Antiobesity therapeutics with complementary dual-agonist activities at glucagon and glucagon-like peptide 1 receptors.
- DOI
- 10.1111/dom.14546
- Published
- 2022 Jan
- Container
- Diabetes, obesity & metabolism
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/dom.14546,
title = {Antiobesity therapeutics with complementary dual-agonist activities at glucagon and glucagon-like peptide 1 receptors.},
author = {Park BG and Kim GM and Lee HJ and Ryu JH and Kim DH and Seong JY and Kim S and Park ZY and Kim YJ and Lee J and Kim JI},
year = {2022},
journal = {Diabetes, obesity \& metabolism},
doi = {10.1111/dom.14546},
url = {https://doi.org/10.1111/dom.14546}
}RIS
TY - JOUR TI - Antiobesity therapeutics with complementary dual-agonist activities at glucagon and glucagon-like peptide 1 receptors. AU - Park BG AU - Kim GM AU - Lee HJ AU - Ryu JH AU - Kim DH AU - Seong JY AU - Kim S AU - Park ZY AU - Kim YJ AU - Lee J AU - Kim JI PY - 2022 JO - Diabetes, obesity & metabolism DO - 10.1111/dom.14546 UR - https://doi.org/10.1111/dom.14546 ER -
APA
BG, P., GM, K., HJ, L., JH, R., DH, K., JY, S., S, K., ZY, P., YJ, K., J, L., & JI, K. (2022). Antiobesity therapeutics with complementary dual-agonist activities at glucagon and glucagon-like peptide 1 receptors.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.14546
Source records
- pubmed · retrieved 2026-09-26T19:04:32.712Z
- europe-pmc · retrieved 2026-09-26T19:04:32.736Z